Mars B. vanʼt Veer

6.0k citations

59 papers · 3.8k indexed · 1 hit paper · h-index 24

Pathology and Forensic Medicine top 0.5%
Oncology top 2%
Pulmonary and Respiratory Medicine top 5%
Public Health, Environmental and Occupational Health top 2%
Pediatrics, Perinatology and Child Health top 2%

Co-authors: Flora E. van Leeuwen Berthe M.P. Aleman Willem J. Klokman Alexandra W. van den Belt‐Dusebout Harry Bartelink Eero Pukkala Charles F. Lynch Eric J. Holowaty
Topics: Lymphoma Diagnosis and Treatment (22 papers)Acute Myeloid Leukemia Research (14 papers)Acute Lymphoblastic Leukemia research (12 papers)
Cited by: Pathology and Forensic Medicine Hematology Oncology
Journals: JAMA Journal of Clinical Oncology Blood
Partner nations: Netherlands United States Germany

In The Last Decade

Mars B. vanʼt Veer

58 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease

2003 504 citations Berthe M.P. Aleman, Willem J. Klokman et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Mars B. vanʼt Veer

Since Specialization

Citations

This map shows the geographic impact of Mars B. vanʼt Veer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mars B. vanʼt Veer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mars B. vanʼt Veer more than expected).

Fields of papers citing papers by Mars B. vanʼt Veer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mars B. vanʼt Veer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mars B. vanʼt Veer. The network helps show where Mars B. vanʼt Veer may publish in the future.

Co-authorship network of co-authors of Mars B. vanʼt Veer

This figure shows the co-authorship network connecting the top 25 collaborators of Mars B. vanʼt Veer. A scholar is included among the top collaborators of Mars B. vanʼt Veer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mars B. vanʼt Veer. Mars B. vanʼt Veer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial 2020 ·British Journal of Haematology ·Jeanette K. Doorduijn,Josée M. Zijlstra,Pieternella J. Lugtenburg,(unknown),Lara H. Böhmer,Monique C. Minnema,Marius MacKenzie,(unknown),(unknown),(unknown),Okke de Weerdt,Michel van Gelder,Mels Hoogendoorn,(unknown),Robby E. Kibbelaar,Daphne de Jong,Dana Chiţu,Mars B. vanʼt Veer,Hanneke C. Kluin‐Nelemans	11
2	Increased Risk of Stroke and Transient Ischemic Attack in 5-Year Survivors of Hodgkin Lymphoma 2009 ·JNCI Journal of the National Cancer Institute ·Marie L. De Bruin,Lucille D.A. Dorresteijn,Mars B. vanʼt Veer,Augustinus D. G. Krol,Helena J. H. van der Pal,A.C. Kappelle,Willem Boogerd,Berthe M.P. Aleman,Flora E. van Leeuwen	159
3	Survival after Hodgkin lymphoma 2009 ·Cancer ·(unknown),Natacha Heutte,Aspasia Stamatoullas‐Bastard,Patrice Carde,Mars B. vanʼt Veer,Berthe M.P. Aleman,(unknown),José Thomas,Christophe Fermé,M. Henry‐Amar	57
4	Cumulative Absolute Breast Cancer Risk for Young Women Treated for Hodgkin Lymphoma 2005 ·JNCI Journal of the National Cancer Institute ·Lois B. Travis,Deirdre A. Hill,Graça M. Dores,Mary Gospodarowicz,Flora E. van Leeuwen,Eric J. Holowaty,Bengt Glimelius,Michael Andersson,Eero Pukkala,Charles F. Lynch,David Pee,Susan A. Smith,Mars B. vanʼt Veer,Timo Joensuu,Hans H. Storm,Marilyn Stovall,John D. Boice,Ethel S. Gilbert,Mitchell H. Gail	280
5	Breast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease 2003 ·JAMA ·Lois B. Travis,Deirdre A. Hill,Graça M. Dores,Mary Gospodarowicz,Flora E. van Leeuwen,Eric J. Holowaty,Bengt Glimelius,Michael Andersson,Tom Wiklund,Charles F. Lynch,Mars B. vanʼt Veer,Ingrid Glimelius,Hans H. Storm,Eero Pukkala,Marilyn Stovall,Rochelle E. Curtis,John D. Boice,Ethel S. Gilbert	457
6	Visual scoring versus histogram subtraction of in vivo binding of immunoglobulins against platelets after transfusion 2003 ·Cytometry Part B Clinical Cytometry ·Mark‐David Levin,Bronno van der Holt,(unknown),Jan W. Gratama,W. de Vries,Mars B. vanʼt Veer	2
7	SIHONSCORE: a scoring system for external quality control of leukaemia/lymphoma immunophenotyping measuring all analytical phases of laboratory performance 2001 ·British Journal of Haematology ·Hanneke C. Kluin‐Nelemans,Elisabeth R. van Wering,C. Ellen van der Schoot,H. J. Adriaansen,Mars B. vanʼt Veer,Jacques J. M. van Dongen,Jan W. Gratama,(unknown)	7
8	Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy 2001 ·British Journal of Haematology ·M. C. Kappers‐Klunne,Mars B. vanʼt Veer	90
9	Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients 2001 ·British Journal of Haematology ·Marie C. Béné,Michel Bernier,Olivier Casasnovas,Gianluigi Castoldi,(unknown),Bronno van der Holt,Walter Knapp,P Lemež,Wolf‐Dieter Ludwig,Estella Matutes,Alberto Órfão,Claudia Schoch,Christian Sperling,Mars B. vanʼt Veer,(unknown)	52
10	Long-Term Risk of Second Malignancy in Survivors of Hodgkin’s Disease Treated During Adolescence or Young Adulthood 2000 ·Journal of Clinical Oncology ·Flora E. van Leeuwen,Willem J. Klokman,Mars B. vanʼt Veer,Anton Hagenbeek,Augustinus D. G. Krol,(unknown),Michael Schaapveld,P. van Heerde,J. M. V. Burgers,R. Somers,Berthe M.P. Aleman	302
11	A Population-Based Case-Cohort Study of Drug-Associated Agranulocytosis 1999 ·Archives of Internal Medicine ·Melanie M. van der Klauw,R Goudsmit,M. Ruud Halie,Mars B. vanʼt Veer,Ron M. C. Herings,J. H. P. Wilson,Bruno H. Stricker	122
12	Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. 1997 ·Journal of Clinical Oncology ·A. W. Dekker,Mars B. vanʼt Veer,W Sizoo,H. L. Haak,J. van der Lelie,G. J. Ossenkoppele,P.C. Huijgens,H. Schouten,Pieter Sonneveld,Roel Willemze,LF Verdonck,W L van Putten,Bob Löwenberg	49
13	Low-Dose rIL-2-Induced Remission of Disseminated CD30+ Anaplastic Large-Cell Lymphoma Through Reinforcement of Presumed T-Cell-Mediated Tumor Cell Killing, Complicated by Unilateral Drowning of Lymphoma-Infiltrated Lung 1996 ·Journal of Immunotherapy ·(unknown),(unknown),(unknown),Jan‐Willem Gratama,(unknown),Mars B. vanʼt Veer	2
14	High-dose therapy followed by bone marrow transplantation for relapsed follicular non-hodgkin's lymphoma 1996 ·Annals of Hematology ·H Schouten,(unknown),Hanneke C. Kluin‐Nelemans,H van Kamp,W. A. M. Mellink,Mars B. vanʼt Veer	12
15	AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients 1995 ·Annals of Hematology ·Christine M. Segeren,(unknown),Mars B. vanʼt Veer	12
16	Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission. 1994 ·Journal of Clinical Oncology ·A.C. Lambrechts,(unknown),Lambert C. J. Dorssers,Mars B. vanʼt Veer	44
17	The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts 1992 ·Annals of Hematology ·Mars B. vanʼt Veer	26
18	Quality assessment of immunological marker analysis and the immunological diagnosis in leukaemia and lymphoma: a multi‐centre study 1992 ·British Journal of Haematology ·Mars B. vanʼt Veer,Hanneke C. Kluin‐Nelemans,C. Ellen van der Schoot,Wim L.J. van Putten,H. J. Adriaansen,Elisabeth R. van Wering	22
19	Double Marker Analysis for Terminal Deoxynucleotidyl Transferase and Myeloid Antigens in Acute Nonlymphocytic Leukemia Patients and Healthy Subjects 1990 ·Hämatologie und Bluttransfusion ·Henk J Adriaansen,Herbert Hooijkaas,M. C. Kappers‐Klunne,K. Hählen,Mars B. vanʼt Veer,Jacques J. M. van Dongen	14
20	Childhood leukaemia in The Netherlands, 1973–1986: Temporary variation of the incidence of acute lymphocytic leukaemia in young children 1989 ·British Journal of Cancer ·J.W.W. Coebergh,A van der Does-van den Berg,Elisabeth R. van Wering,H A van Steensel-Moll,H. A. Valkenburg,Mars B. vanʼt Veer,(unknown),G E van Zanen	27

About Mars B. vanʼt Veer

Mars B. vanʼt Veer is a scholar working on Hematology, Pathology and Forensic Medicine and Genetics, having authored 59 papers that have together received 3.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (22 papers), Acute Myeloid Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (12 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.7k citations), Hematology (607 citations) and Oncology (1.0k citations). Mars B. vanʼt Veer has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Flora E. van Leeuwen, Berthe M.P. Aleman, Willem J. Klokman, Alexandra W. van den Belt‐Dusebout, Harry Bartelink, Eero Pukkala, Charles F. Lynch, Eric J. Holowaty, Bengt Glimelius and Lois B. Travis. Their work appears in journals such as JAMA, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact